Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D King

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
The Journal of Pain|November 19, 2013
Age and race effects on pain sensitivity and modulation among middle-aged and older adultsJoseph L Riley, Yenisel Cruz-Almeida, Toni L Glover, et al.
Brain, Behavior, and Immunity|December 20, 2025
Brain-immune correlates of quality of life in adolescents with chronic musculoskeletal painSaül Pascual-Diaz, Maria Suñol, Marie-Eve Hoeppli, et al.
Experimental Gerontology|August 27, 2017
Physical performance and movement-evoked pain profiles in community-dwelling individuals at risk for knee osteoarthritisYenisel Cruz-Almeida, Josue Cardoso, Joseph L Riley, et al.
Arthritis Care & Research|October 6, 2015
Enhanced Pain Sensitivity Among Individuals With Symptomatic Knee Osteoarthritis: Potential Sex Differences in Central SensitizationEmily J Bartley, Christopher D King, Kimberly T Sibille, et al.
Journal of Medicinal Chemistry|November 9, 2011
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitorNicholas S Stock, Gretchen Bain, Jasmine Zunic, et al.
Journal of Medicinal Chemistry|May 5, 2017
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)Martin W Rowbottom, Gretchen Bain, Imelda Calderon, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2014
Racial and ethnic differences in older adults with knee osteoarthritisYenisel Cruz-Almeida, Kimberly T Sibille, Burel R Goodin, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lungKarin J Stebbins, Alex R Broadhead, Christopher S Baccei, et al.
Pain Reports|February 3, 2018
Accelerated aging in adults with knee osteoarthritis pain: consideration for frequency, intensity, time, and total pain sitesKimberly T Sibille, Huaihou Chen, Emily J Bartley, et al.
European Journal of Pharmacology|June 4, 2010
Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammationDaniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
The Journal of Pain|November 19, 2013
Age and race effects on pain sensitivity and modulation among middle-aged and older adultsJoseph L Riley, Yenisel Cruz-Almeida, Toni L Glover, et al.
Brain, Behavior, and Immunity|December 20, 2025
Brain-immune correlates of quality of life in adolescents with chronic musculoskeletal painSaül Pascual-Diaz, Maria Suñol, Marie-Eve Hoeppli, et al.
Experimental Gerontology|August 27, 2017
Physical performance and movement-evoked pain profiles in community-dwelling individuals at risk for knee osteoarthritisYenisel Cruz-Almeida, Josue Cardoso, Joseph L Riley, et al.
Arthritis Care & Research|October 6, 2015
Enhanced Pain Sensitivity Among Individuals With Symptomatic Knee Osteoarthritis: Potential Sex Differences in Central SensitizationEmily J Bartley, Christopher D King, Kimberly T Sibille, et al.
Journal of Medicinal Chemistry|November 9, 2011
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitorNicholas S Stock, Gretchen Bain, Jasmine Zunic, et al.
Journal of Medicinal Chemistry|May 5, 2017
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)Martin W Rowbottom, Gretchen Bain, Imelda Calderon, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 15, 2014
Racial and ethnic differences in older adults with knee osteoarthritisYenisel Cruz-Almeida, Kimberly T Sibille, Burel R Goodin, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lungKarin J Stebbins, Alex R Broadhead, Christopher S Baccei, et al.
Pain Reports|February 3, 2018
Accelerated aging in adults with knee osteoarthritis pain: consideration for frequency, intensity, time, and total pain sitesKimberly T Sibille, Huaihou Chen, Emily J Bartley, et al.
European Journal of Pharmacology|June 4, 2010
Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammationDaniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
Pageof 11